{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T10:33:37Z","timestamp":1774089217048,"version":"3.50.1"},"reference-count":36,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,10,15]]},"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To analyse the temporal and geographical diffusion of antivascular endothelial growth factor (anti-VEGF) interventions, and its determinants in a National Health System (NHS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>NHS Portuguese hospitals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>All inpatient and day cases related to eye diseases at all Portuguese public hospitals for the period 2002\u20132012 were selected on the basis of four International Classification of Diseases 9th revision, Clinical Modification (ICD-9-CM) codes for procedures: 1474, 1475, 1479 and 149.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>We measured anti-VEGF treatment rates by year and county. The determinants of the geographical diffusion were investigated using generalised linear modelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We analysed all hospital discharges from all NHS hospitals in Portugal (98\u2005408 hospital discharges corresponding to 57\u2005984 patients). National rates of hospitals episodes for the codes for procedures used were low before anti-VEGF approval in 2007 (less than 12% of hospital discharges). Between 2007 and 2012, the rates of hospital episodes related to the introduction of anti-VEGF injections increased by 27% per year. Patients from areas without ophthalmology departments received fewer treatments than those from areas with ophthalmology departments. The availability of an ophthalmology department in the county increased the rates of hospital episodes by 243%, and a 100-persons greater density per km\n                      <jats:sup>2<\/jats:sup>\n                      raised the rates by 11%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study shows a large but unequal diffusion of anti-VEGF treatments despite the universal coverage and very low copayments. The technological innovation in ophthalmology may thus produce unexpected inequalities related to financial constraints unless the implementation of innovative techniques is planned and regulated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-009006","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T21:29:09Z","timestamp":1448314149000},"page":"e009006","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Diffusion of anti-VEGF injections in the Portuguese National Health System"],"prefix":"10.1136","volume":"5","author":[{"given":"Ana Patr\u00edcia","family":"Marques","sequence":"first","affiliation":[{"name":"Escola Nacional de Sa\u00fade P\u00fablica, Universidade NOVA de Lisboa, Lisbon, Portugal"}]},{"given":"Ant\u00f3nio Filipe","family":"Macedo","sequence":"additional","affiliation":[{"name":"Vision Rehabilitation Lab, Departamento\/Centro de F\u00edsica, Universidade do Minho, Braga, Portugal"}]},{"given":"Julian","family":"Perelman","sequence":"additional","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o em Sa\u00fade P\u00fablica (CISP), Escola Nacional de Sa\u00fade P\u00fablica, Universidade NOVA de Lisboa, Lisboa, Portugal"}]},{"given":"Pedro","family":"Aguiar","sequence":"additional","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o em Sa\u00fade P\u00fablica (CISP), Escola Nacional de Sa\u00fade P\u00fablica, Universidade NOVA de Lisboa, Lisboa, Portugal"}]},{"given":"Am\u00e2ndio","family":"Rocha-Sousa","sequence":"additional","affiliation":[{"name":"Departamento de \u00d3rg\u00e3os dos Sentidos, Faculdade de Medicina da Universidade do Porto, Alameda Professor Hern\u00e2ni Monteiro, Porto, Portugal"}]},{"given":"Rui","family":"Santana","sequence":"additional","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o em Sa\u00fade P\u00fablica (CISP), Escola Nacional de Sa\u00fade P\u00fablica, Universidade NOVA de Lisboa, Lisboa, Portugal"}]}],"member":"239","published-online":{"date-parts":[[2015,11,23]]},"reference":[{"key":"2025121422145140000_5.11.e009006.1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-300338"},{"key":"2025121422145140000_5.11.e009006.2","doi-asserted-by":"publisher","DOI":"10.1177\/2040622311415895"},{"key":"2025121422145140000_5.11.e009006.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.03.046"},{"key":"2025121422145140000_5.11.e009006.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.11.017"},{"key":"2025121422145140000_5.11.e009006.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.07.053"},{"key":"2025121422145140000_5.11.e009006.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(92)31871-8"},{"key":"2025121422145140000_5.11.e009006.7","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.58"},{"key":"2025121422145140000_5.11.e009006.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.12.016"},{"key":"2025121422145140000_5.11.e009006.9","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.6.819"},{"key":"2025121422145140000_5.11.e009006.10","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-002-0104-y"},{"key":"2025121422145140000_5.11.e009006.11","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.2.264"},{"key":"2025121422145140000_5.11.e009006.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068185"},{"key":"2025121422145140000_5.11.e009006.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.05.030"},{"key":"2025121422145140000_5.11.e009006.14","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6644"},{"key":"2025121422145140000_5.11.e009006.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042760"},{"key":"2025121422145140000_5.11.e009006.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60282-7"},{"key":"2025121422145140000_5.11.e009006.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.06.020"},{"key":"2025121422145140000_5.11.e009006.18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00717-012-0072-2","article-title":"The intravitreal injection: variations in regulations, cost and reimbursement in Europe","volume":"26","author":"Michels","year":"2012","journal-title":"Spektrum Augenheilkd"},{"key":"2025121422145140000_5.11.e009006.19","doi-asserted-by":"crossref","first-page":"319728","DOI":"10.1155\/2012\/319728","article-title":"Antivascular endothelial growth factor agents for neovascular age-related macular degeneration","volume":"2012","author":"Zampros","year":"2012","journal-title":"J Ophthalmol"},{"key":"2025121422145140000_5.11.e009006.20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/OPTH.S31016","article-title":"Emerging roles for antiangiogenesis factors in management of ocular disease","volume":"6","author":"Saeed","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"2025121422145140000_5.11.e009006.21","doi-asserted-by":"crossref","first-page":"786870","DOI":"10.1155\/2012\/786870","article-title":"Anti-VEGF treatment strategies for wet AMD","volume":"2012","author":"Kovach","year":"2012","journal-title":"J Ophthalmol"},{"key":"2025121422145140000_5.11.e009006.22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/0264619613481778","article-title":"Living with age-related macular degeneration treatment: patient experiences of being treated with ranibizumab (Lucentis)(R) intravitreal injections","volume":"31","author":"Thetford","year":"2013","journal-title":"Br J Vis Impairm"},{"key":"2025121422145140000_5.11.e009006.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e2970"},{"key":"2025121422145140000_5.11.e009006.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.10.003"},{"key":"2025121422145140000_5.11.e009006.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.08.012"},{"key":"2025121422145140000_5.11.e009006.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.10.036"},{"key":"2025121422145140000_5.11.e009006.27","unstructured":"INE. Censos \u2013 Resultados definitivos. Portugal\u20142011, 2014 (cited 28 April 2014). http:\/\/www.ine.pt\/xportal\/xmain?xpid=INE&xpgid=ine_publicacoes&PUBLICACOESpub_boui=73212469&PUBLICACOESmodo=2"},{"key":"2025121422145140000_5.11.e009006.28","unstructured":"Beaghole R , Bonita R , Kjellstrom T . Basic epidemiology. Updated reprint ed. Geneva: World Health Organization, 1993."},{"key":"2025121422145140000_5.11.e009006.29","doi-asserted-by":"publisher","DOI":"10.1177\/1094428104263672"},{"key":"2025121422145140000_5.11.e009006.30","unstructured":"Ministry of Health. Portal da Sa\u00fade. Lisboa: Health Ministry, 2014 (cited 10 January 2014). http:\/\/www.portaldasaude.pt\/portal"},{"key":"2025121422145140000_5.11.e009006.31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/NNR.0b013e3181e507f1","article-title":"An application of longitudinal analysis with skewed outcomes","volume":"59","author":"Azuero","year":"2010","journal-title":"Nurs Res"},{"key":"2025121422145140000_5.11.e009006.32","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2013.0832"},{"key":"2025121422145140000_5.11.e009006.33","unstructured":"Hawlina M . UEMS survey highlights accessibility disparities, inconsistent policies for anti-VEGF treatment across Europe. Ocular Surgery News Europe Edition, 2015:5."},{"key":"2025121422145140000_5.11.e009006.34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1442-9071.2005.01085.x","article-title":"Factors related to non-attendance in a public eye clinic","volume":"33","author":"Koppens","year":"2005","journal-title":"Clin Experiment Ophthalmol"},{"issue":"(Suppl 7)","key":"2025121422145140000_5.11.e009006.35","first-page":"III65","article-title":"Rural-urban differences in usual source of care and ambulatory service use: analyses of national data using urban influence codes","volume":"41","author":"Larson","year":"2003","journal-title":"Med Care"},{"key":"2025121422145140000_5.11.e009006.36","doi-asserted-by":"publisher","DOI":"10.1177\/193229680900300209"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-009006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:15:01Z","timestamp":1765779301000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-009006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11,23]]},"published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1136\/bmjopen-2015-009006"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-009006","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}